| DB ID | MyCo_1608 |
| Title | Detection of urinary excreted fungal galactomannan-like antigens for diagnosis of invasive aspergillosis |
| Year | 2012 |
| PMID | 22900046 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | Mouse experiments were conducted at the Albert Einstein College of Medicine, Bronx, NY, following a protocol approved by the Institutional Animal Care and Use Committee (IACUC) of that institution (Protocol number: 20090404); imaging procedures were performed under isofluorane anesthesia according to protocol. Experiments with the Guinea Pig model of invasive aspergillosis were conducted at the San Antonio Center for Medical Mycology of the University of Texas Health Science Center, following protocols approved by IACUC (Protocol number: 00101G). All studies involving human urine samples were approved by the Johns Hopkins Medicine Institutional Review Board (IRB) (collection of urine from consented human volunteers, study number: NA_00029178; use of previously collected, de-identified, banked urine samples, study number: NA_00027228); written consent forms are in file. |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Urine |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM-reactive MAb476 |
| Biomarker Full Name | Galactomannan-reactive Monoclonal Antibody 476 |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | USA |
| Cohort | Urine samples were obtained from 6 healthy adult volunteers (numbered VU1-6). One clinical sample from a patient with probable IA was collected with consent at Johns Hopkins Hospital. We also used banked (280uC) urine samples from a study conducted at Fred Hutchinson Cancer Research Center, Seattle, WA; patients participating in this study, all diagnosed with IA, had urine collected every 8 h for 3 consecutive days. Of these, we selected urine samples from 10 patients (proven/probable IA) with GMEIA positive serum. |
| Cohort No. | None |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Mortality associated with invasive aspergillosis (IA) is high despite availability of potent antifungal drugs. Delayed diagnosis partly contributes to this poor outcome, since classical microbiological methods are insensitive. Culture-independent detection of several fungal components have shown promise for earlier diagnosis. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | ‘GM-EIA’ Platelia Aspergillus EIA, BioRad Inc., Hercules, CA. |
| Assay Data | None |
| Validation Techniques used | ELISA, LFD |
| Up Regulation Down Regulation | None |
| Sequence Data | None |
| External Link | None |
